<DOC>
	<DOCNO>NCT02908620</DOCNO>
	<brief_summary>The purpose study determine topical application cheek tissue combination benzocaine tetracaine long duration local anesthetic activity benzocaine alone .</brief_summary>
	<brief_title>Experimental Pain Study Assess Local Anesthetic Efficacy Safety CTY-5339 Anesthetic Spray Normal Volunteers</brief_title>
	<detailed_description>In blind study , either benzocaine alone combination benzocaine tetracaine spray onto cheek mucosal tissue . Onset duration local anesthesia evaluate one hour period use pin prick QST heat stimulation . Subjects receive treatment cross-over design session separate 5-7 day . A total 76 subject ( normal volunteer ) evaluate .</detailed_description>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Tetracaine</mesh_term>
	<mesh_term>Benzocaine</mesh_term>
	<mesh_term>Anesthetics , Local</mesh_term>
	<criteria>Male female subject 1875 year age Body Mass Index ( BMI ) â‰¤32 ; Subjects ASA Category I II normal physical health judge physical laboratory examination ; Subjects normal appearance oral mucosal tissue ; Subjects must agree refrain ingest systemic topical analgesic medication 3 day 5 halflives drug prior study period alcohol 1 day prior study period ; Subjects must agree refrain use mouth rinse , cough drop throat lozenges day test session ; Female subject must physically incapable childbearing potential ( postmenopausal 1 year surgically sterile ) practice acceptable method contraception ( hormonal , barrier spermicide , intrauterine device , vasectomized sex partner , abstinence ) . Subjects use hormonal birth control must stable dose treatment least 30 day receive least 1 cycle treatment prior randomization . At Screening Baseline session , female childbearing potential must negative urine pregnancy test breastfeeding ; Negative urine drug screen drug abuse Screening Baseline Study Session . A positive drug screen result may permit subject stable dose allow medication &gt; 30 day ; The subject capable reading , comprehend , sign informed consent form . Subjects history significant hepatic , renal , endocrine , cardiac , neurological , psychiatric , gastrointestinal , pulmonary , hematologic , metabolic disorder , include glaucoma , diabetes , emphysema , chronic bronchitis ; Subjects history type cancer skin relate cancer ; Subjects condition affect absorption , metabolism , passage drug body , ( e.g. , sprue , celiac disease , Crohn 's disease , colitis , liver , kidney , thyroid condition ) ; Subjects history alcohol substance abuse ( include positive drug screen test ) ; Subjects currently history uncontrolled hypertension ; Subjects know hypersensitivity local anesthetic drug ; Subjects hematocrit level significantly normal range screen laboratory examination ( judged PI ) ; Subjects clinically significant abnormal lab result ( judge PI ) ; Subjects condition history felt Investigator place subject increase risk ; Subjects smoke chew tobaccocontaining substance within 6 month prior start study ; Subjects judge Investigator unable unwilling comply requirement protocol ; Subjects use investigational drug within 30 day prior enter study ; Subjects donate blood within 3 month prior start study ; Subjects previously participate trial ; Subjects member study site staff directly involve study relative Sponsor personnel involve study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>